N-benzyl-N-methyl-1-phenylmethanamine: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 21583 |
| CHEMBL ID | 2106280 |
| SCHEMBL ID | 276863 |
| SCHEMBL ID | 6555649 |
| MeSH ID | M0212339 |
| Synonym |
|---|
| AKOS005427167 |
| BB 0259303 |
| n-benzyl-n-methyl-1-phenylmethanamine |
| inchi=1/c15h17n/c1-16(12-14-8-4-2-5-9-14)13-15-10-6-3-7-11-15/h2-11h,12-13h2,1h |
| l 566 |
| dibenzylamine, n-methyl- |
| dbma |
| nsc163900 |
| n,n-dibenzylmethylamine |
| dibemethine |
| revoxyl |
| dibemethin |
| n-methyldibenzylamine |
| benzenemethanamine, n-methyl-n-(phenylmethyl)- |
| n-methyl-n,n-dibenzylamine |
| dibenzylmethylamine |
| methyldibenzylamine |
| nsc-163900 |
| 102-05-6 |
| NCGC00160569-01 |
| STK283922 |
| n-methyl dibenzylamine |
| dibemethine [inn:dcf] |
| dibemethinum |
| 67vkg5dy8w , |
| einecs 203-001-6 |
| nsc 163900 |
| unii-67vkg5dy8w |
| dibemetina |
| ai3-26795 |
| dibemetina [inn-spanish] |
| dibemethinum [inn-latin] |
| dtxcid2026238 |
| dtxsid4046238 , |
| tox21_111907 |
| cas-102-05-6 |
| CHEMBL2106280 |
| l-566 |
| methyl dibenzylamine |
| S11701 |
| SCHEMBL276863 |
| dibemethine [inn] |
| n-benzyl-(+)-methyl-benzylamine |
| SCHEMBL6555649 |
| dibenzyl methyl amine |
| n-benzyl-n-methylphenylmethanamine # |
| W-108888 |
| mfcd00022018 |
| n-benzyl-n-methylphenylmethanamine |
| AS-13057 |
| BRD-K01772856-003-01-7 |
| Q27264173 |
| SB78736 |
| CS-0151256 |
| SY104827 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID504749 | qHTS profiling for inhibitors of Plasmodium falciparum proliferation | 2011 | Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043 | Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | 2014 | Journal of biomolecular screening, Jul, Volume: 19, Issue:6 | A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (39.25) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||